UNSPSC 51421506: Loteprednol etabonate

This classification denotes a therapeutic glucocorticoid with the molecular formula C24H31ClO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YEH1EZ96K6, chemically known as chloromethyl 17a-ethoxycarbonyloxy-11b-hydroxyandrosta-1,4-diene-3-one-17b-carbo but more generally known as loteprednol etabonate, which bears US NIH Compound Identifier 54808. European Medicines Agency schedules Loteprednol etabonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14390MIG.

UNSPSC 51421506 Loteprednol etabonate is a Commodity code for a specific ophthalmic corticosteroid pharmaceutical product; however, the recent state and local opportunities tagged to this code show a substantial mismatch between the nominal scope and actual procurement activity. The two posted opportunities involve naloxone procurement and direct-to-manufacturer prescription program design — neither directly related to loteprednol etabonate supply. State and local governments buying under this code designation are primarily counties and state health authorities, but the recent posting activity does not support a clear picture of loteprednol etabonate-specific demand. Seminole County, Florida, and the Texas Health and Human Services Commission are the identifiable recent issuing bodies, though their current procurements address opioid-reversal drugs and pharmacy benefit structure rather than the ophthalmic steroid the code nominally describes.

The geographic spread evident in recent postings is limited to Florida and Texas. Seminole County issued an Invitation for Bids (IFB 60459723LAS) in June 2026 for annual naloxone and drug deactivation system procurement with quarterly deliveries to Sanford, Florida, and a response deadline of July 26, 2026. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) in April 2026 to assess vendor capacity for direct-to-manufacturer prescription contracting. The code shows little relevant recent activity aligned with loteprednol etabonate supply; the posted opportunities suggest either systematic coding error or that state and local loteprednol procurement is not currently visible in the indexed opportunity stream.